Response to Stahlie et al regarding "A systematic review and meta-analysis of locoregional treatments for in-transit melanoma"

Abstract

To the Editor, We wish to thank Stahlie et al1 for their interest in our article. We did not include intralesional talimogene laherparepvec (T‐VEC) therapy in our analysis as we focused on locoregional treatments available in Australia and New Zealand. However, we commend them on highlighting the promising clinical results for T‐VEC. Since completing our systematic review, four studies have been published and these underscore the value of this treatment for patients with advanced disease.2-5 Additionally, the combination of T‐VEC with systemic immunotherapies including pembrolizumab will provide further evidence concerning their efficacy and safety profiles and preliminary results support this approach.6 Such combinations will also generate novel data that further define the survival outcomes of these patients.